Research on Compulsory Drug Patent Licensing in China Under Covid-19

DOI

10.2991/assehr.k.200826.082How to use a DOI?

Keywords

covid-19, drug patents, the compulsory license, the applicant, licensing procedures

Abstract

Covid-19 has spread in China and quickly spread to the world. The world health organization (WHO) has listed it as a public health emergency of international concern. In the face of this serious pandemic, global public security has been seriously threatened, and it is imperative to address the supply of medicines. This paper starts with the current situation of covid-19, compares the practice of compulsory drug patent licensing in different countries, and finds out the deficiency of compulsory drug patent licensing in China. Then put forward feasible suggestions for drug patent compulsory licensing.

Copyright

© 2020, the Authors. Published by Atlantis Press.

Open Access

This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

TY  - CONF
AU  - Zhou Zhide
AU  - Yu Shanshan
PY  - 2020
DA  - 2020/08/28
TI  - Research on Compulsory Drug Patent Licensing in China Under Covid-19
BT  - Proceedings of the 2020 4th International Seminar on Education, Management and Social Sciences (ISEMSS 2020)
PB  - Atlantis Press
SP  - 415
EP  - 417
SN  - 2352-5398
UR  - https://doi.org/10.2991/assehr.k.200826.082
DO  - 10.2991/assehr.k.200826.082
ID  - Zhide2020
ER  -